Skip to content
Screener

Veracyte VCYT Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$131.9MMiss by $3.9M
EPS$0.51Beat by $0.19
Revenue estimate$135.8M
EPS estimate$0.32

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$147.2M
EPS estimate$0.43

Financials

Q3 2025

Income statement

See full
Revenue$131.9M+13.8%
Gross profit$91.3M+15.5%
Operating income$22.9M+90.9%
Net income$19.1M+26.3%
EPS (diluted)$0.24+26.3%

Balance sheet

See full
Cash & equivalents$317.2M+15.3%
Total debt$40.5M+104%
Total equity$1.3B+6.9%
Total assets$1.4B+7.3%

Cash flow

See full
Operating cash flow$44.8M+49.4%
CapEx$2.8M+24.5%
Free cash flow$42.0M+51.4%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.7B+3.7%
Enterprise value$2.42B+3.2%
P/E89.1×—
P/S5.5×-0.7×

Profitability

See full
Gross margin68.5%+1.7pp
Operating margin5%+3.3pp
Net margin6.1%+4.8pp
FCF margin19.8%+6.6pp

Returns & leverage

See full
Return on equity2.5%+2.0pp
Debt / equity0×0.0×
Current ratio6.2×+1.2×

Segments

By segment

See full
Reportable Segment$131.9M+13.8%

By geography

See full
United States$124.1M+17.3%

By product

See full
Testing revenue$127.8M+16.6%

FAQ

When did Veracyte report Q3 2025 earnings?
Veracyte (VCYT) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Veracyte's Q3 2025 revenue and EPS?
Veracyte reported revenue of $131.9M and eps of $0.51 for Q3 2025.
Did Veracyte beat estimates in Q3 2025?
Revenue missed the consensus estimate of $135.8M by $3.9M. EPS beat the consensus estimate of $0.32 by $0.19.
How did Veracyte's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.8% from $115.9M a year earlier and eps grew 168.4% from $0.19.
Where can I find Veracyte's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001384101-25-000128) and the 10-Q periodic report (0001384101-25-000130) directly on SEC EDGAR. The filing index links above go to sec.gov.